E34Analysis of clinical outcomes according to mutation subtype in EGFR-positive advanced non-small cell lung cancer (aNSCLC) patients treated with EGFR Tyrosine Kinases Inhibitors (TKIs) as first line
ANNALS OF ONCOLOGY（2017）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要